There is concern that bluish skin discoloration associated with ezogabine treatment could be permanent.
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Introduction
Ezogabine (EZG; North American adopted name), also known as retigabine (RTG; international nonproprietary name), is an anti-seizure drug (AED) that was approved as adjunctive treatment for focalonset seizures in March 2011 in Europe and in June 2011 in the United States. EZG/RTG is a neuronal potassium channel opener with a primary mechanism of action as a positive allosteric modulator of KCNQ2-5 (Kv7.2-7.5) ion channels thereby causing hyperpolarization and reduced firing of highfrequency action potentials [1] . In vitro studies have also suggested that EZG/RTG enhanced inhibitory effects of gamma-aminobutyric acid (GABA) by modulating GABA A receptors [1] . The efficacy of EZG/RTG (600, 900 and 1200 mg/day) as adjunctive therapy in patients with focal-onset seizures has been demonstrated in three randomized, double-blind, placebo-controlled trials [2] [3] [4] .
The most frequently reported drug-related adverse reactions, reported by more than 10% of patients, in the regulatory placebo-controlled trials were the nonspecific dizziness, somnolence, and fatigue at 600
and 900 mg per day [2] , as well as confusional state, dysarthria, ataxia, blurred vision, tremor and nausea at 1200 mg per day [3] . EZG/RTG also had relatively unique adverse effects, such as urinary retention, presumed related to effect on potassium channels in bladder smooth muscle [5] , and abnormal pigmentation. The latter was reported in an FDA-issued warning in 2013, stating that EZG/RTG can cause retinal pigment changes and blue discoloration of the skin [6] . The warning did not provide information on the natural course of this pigmentation after discontinuation of EZG/RTG, and little is known about the reversibility of skin pigmentation.
We present a case of EZG/RTG induced skin discoloration that resolved almost completely after discontinuation of EZG/RTG.
Case report
A 55 year old woman developed focal seizures at 21 years of age. Early seizures consisted of a blank stare, confusion, then wandering about. They recurred approximately four times a week for one year, 
Discussion
Discoloration of the skin, nails, mucosa and retinal pigmentary abnormalities as an adverse effect of EZG/ RTG have been described in the literature since 2014. The first report was of two patients with blue-gray skin dyspigmentation that was most pronounced on the face and lips [7] . There was also pigmentation on the nails, blue pigmentation on the hard palate, and black pigment deposits on the conjunctivae.
Histopathologically, the main finding was that dermal cells were heavily laden with coarse melanin granules, mainly in peri-vascular and peri-eccrine distribution. Biopsy of the hard palate showed coarse pigment in the submucosa, inside macrophages as well as in the extracellular matrix, positive for melanin [7] . Another case report that followed described bluish purple discoloration of the fingernails and hard palate after 2 years of treatment with EZG/RTG [8] . Our patient first reported bluish pigmentation after 5 years of treatment. Pigmentation was also reported in the retina and other mucosal membranes, including urinary bladder [6, 9] . Experimental studies on albino and pigmented rats suggest that the cause of skin discoloration is accumulation of free and/or melanin-bound pigment dimers of EZG/RTG and its N-acetyl metabolite [9] . The pigmentation changes seem to be time and dose dependent. The most updated prescribing information reported approximately 10% of patients in long-term clinical trials developed skin discoloration, generally after 2 or more years of treatment and at higher doses of 900 mg or more per day [10] . However, a study available only in abstract form indicated that 108 out of 365 (30%) subjects examined had discoloration of lips, nails, skin, or mucosa, with a median time to onset of 4.4 years [11] .
The FDA safety report suggested that skin discoloration may become permanent [12] . However, there were no data to support the notion that the discoloration is permanent. The first report on skin A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT discoloration described improvement in skin, oral mucosa and nail discoloration four months after stopping EZG/RTG in one patient. There have not been further published reports on reversibility of the skin discoloration. Our subject demonstrates that skin discoloration caused by EZG/RTG is reversible following discontinuation of this medication. Improvement was noted in our patient within 6 months, with eventual total resolution within 6 years. While these findings are encouraging, they will have to be confirmed with additional observations in patients who have stopped EZG/RTG after developing skin pigmentation.
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